4 HUGE Gainers to Watch Today 💫

These stocks are skyrocketing to triple-digit gains in today's premarket.                                                                                                                                                                                                                                                                                                                                                                                                                 March 07, 2024 | [Read Online]( Good Morning! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Let’s get ready to trade! Markets 📈 Stocks returned to form on Wednesday thanks to dovish comments from Fed Chair Jerome Powell during his testimony to Congress. - Dow [-0.2%] - S&P 500 [-0.5%] - Nasdaq [-0.5%] - Russell 2K [-0.7%] Futures are up in early trading. S&P 500 contracts are showing a 0.2% gain. What to Watch Today: Jerome Powell will head to Congress for a second day of testimony today. The Fed Chairman boosted the market on Wednesday when he indicated that there is a path ahead for rate cuts this year. Powell’s comments today could drive more volatility in the trading session. We’ll also get some high-profile earnings reports after the closing bell, which could shake up tomorrow’s premarket. [Eye-Popping 96% Win Rate for Simple Options]( When smart traders win 96% of their options trades... with this simple system... Could this be the easiest trading system ever? It's not complicated. It's not some weird AI indicator. It's not about spending hours glued to a trading chart. Instead, it's a system that wins 96% of the time. [Get Started on the Next Page »]( » Want an Ad-Free Experience + Top Growth Stock Picks? [Upgrade Now!]( Premarket Highlights 🔎 🚗 Tesla's Market Position Takes a Detour Tesla Motors [TSLA] has begun its day with a slight downturn in premarket trading, hinting at a continuation of its recent challenges on the stock market. This latest dip is part of a broader trend that has seen the electric vehicle (EV) pioneer drift from its high-flying market standings. 🏆 Out of the Top 10 Wednesday's trading session saw Tesla's stock fall by 2.3%, dragging its market capitalization down to $562.2 billion. This shift resulted in Tesla being overtaken by Visa in terms of market size, a significant marker since Tesla had not fallen out of the top-10 biggest U.S. companies by market cap since January 2023, as per Dow Jones Market Data. 💸 A Costly Year Last year was been marked by financial upheaval for Tesla, with the company witnessing a shrinkage of nearly $238 billion in its market cap. This downturn in valuation is reflective of investor reactions and market adjustments in response to a myriad of factors influencing the EV sector and broader stock market sentiments. 🍏 A Comparative Perspective While Tesla's reduction in market cap is noteworthy, it is not the largest loss experienced by a U.S. company this year. Apple holds that dubious honor, having seen its market valuation decrease by nearly $383 billion. Tesla's recent movements in the stock market underscore the volatile nature of tech and EV stocks in the current economic landscape, setting a stage for potential strategic shifts and investor recalibrations. Featured Earnings 💰️ - Kroger [KR] ... Am - Burlington Stores [BURL] ... AM - BJ's Wholesale Club Holdings [BJ] ... AM - Toro [TTC] ... AM - Broadcom [AVGO] ... PM - Costco Wholesale [COST] ... PM - MongoDB [MDB] ... PM - Samsara [IOT] ... PM - DocuSign [DOCU] ... PM - Guidewire Software [GWRE] ... PM Economy 🏗 - Initial jobless claims [Mar] ... 8:30a - U.S. productivity (revision) [Q4] ... 8:30a - U.S. trade balance [Jan] ... 8:30a - Fed Chair Jerome Powell testifies to Congress ... 9:40a - Cleveland Fed President Loretta Mester speaks ... 11:30a - Consumer credit [Jan] ... 3:00p Running Hot 🔥 Gainers - Beneficient [BENF] >> +66.5% - Immunoprecise [IPA] >> +36.0% - Honest Company [HNST] >> +40.3% Decliners - Avid Biosciences [CDMO] >> (32.7%) - Solowin [SWIN] >> (33.7%) - Victoria’s Secret [VSCO] >> (30.1%) CERo Therapeutics [CERO] - Last Close: $2.55 This tiny biotech is skyrocketing after publishing promising clinical research supporting CER-1236 as a treatment for leukemia patients. CERo outlined its findings in a paper titled Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia (AML) published in Clinical Cancer Research medical journal. The study found that CER-1236 “ effectively eliminated leukemic cells in the company’s experiments.“ CERo says its findings support a Phase 1 trial for AML and, potentially, additional therapeutic options for the drug. CERO is up 668.2% on almost a million shares traded. My Take: CERO is seeing enormous gains as a result of this news, but it almost seems too good to be true. Watch for a pull back. Lytus Technologies [LYT] - Last Close: $2.31 After Wednesday’s close, Lotus Technologies announced the launch of a suite of cloud infrastructure services it’s calling the Lytus Cloud. The company says the announcement marks their entrance into the “$326 billion data center market.” LYT is soaring in today’s premarket. It’s up 208.2% on roughly 5 million shares traded. My Take: LYT has a very high short ratio, so I suspect this move is more the result of a short squeeze than the aforementioned news. Brera Holdings [BREA] - Last Close: $1.02 A recent regulatlory disclosure revealed that Brera’s executive chairman and veteran investment banker Daniel McClory has acquired a majority stake. According to the filing, McClory recently acquired 4.6 million shares of stock, bringing his total ownership stake to nearly 55%. He also controls 84% of the company’s total votes. BREA is up 124.5% on over 15 million shares traded. My Take: McClory’s buying spree could indicate he has plans for BREA. Investors could be positioning themselves for a potential buyout or take-private deal sometime in this stocks future. Immuron [IMRN] - Last Close: $1.65 Positive interim top-line data from a Phase 2 trial of IMM-124E (Travelan®) is lifting shares of this tiny biotech this morning. Immuron said the trial produced statistically significant results in several key categories, and the data supports advancement to a Phase 3 trial. The company will now hold an end-of-Phase 2 meeting with the FDA to discuss the pivotal Phase 3 registration strategy and clinical trial plans. IMRN is a top mover with a 94.2% gain on roughly 6 million shares traded. My Take: IMRN looks like it’s on its way to an approval, but it could take a while for the next catalyst to develop. That's it for today! Thanks for reading, and good luck out there! Best Regards, — Chris D. Elite Trade Club Text ELITE to 47121 or [click here]( to get our alerts on your mobile device, and never miss another fast-moving stock! P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. [Sign up for SMS]( Join Insider NOW to access to this report! [Get Instant Access Here]( [tw]( [ig]( [yt]( [tk]( *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Privacy Policy]( | [Terms of Service]( Update your email preferences or unsubscribe [here]( © 2024 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247 Orlando, Florida 32828, United States of America